AFT Pharmaceuticals - Growth in the face of a challenging environment
AFT Pharmaceuticals recently reported its results for FY21. Operating revenue grew strongly by 7% year-on-year to NZ$113.1m, driven mainly by 11% growth in Australia, despite the impact of COVID-19 across the business (especially lower licensing income and higher costs, including freight). Reported group operating profit was NZ$10.7m compared to NZ$21.2m in the same period a year ago (NZ$11.4m if a one-time FY20 gain of NZ$9.8m is excluded). Importantly, AFT is guiding to operating profit of NZ$18–23m in FY21.AFT Pharmaceuticals is engaged in the distribution of pharmaceutical products and the development of pharmaceutical intellectual property.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.